About Capricor Therapeutics, Inc.
https://www.capricor.comCapricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders.
CEO
Linda Marbán
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2019-06-05 | Reverse | 1:10 |
| 2013-11-21 | Reverse | 1:50 |
ETFs Holding This Stock
Summary
Showing Top 3 of 55
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
B. Riley Securities
Buy
Maxim Group
Buy
HC Wainwright & Co.
Buy
Roth Capital
Buy
Jones Trading
Buy
Oppenheimer
Outperform
Grade Summary
Showing Top 6 of 8
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:2.87M
Value:$69M
VANGUARD GROUP INC
Shares:2.21M
Value:$53.05M
BLACKROCK INC.
Shares:1.63M
Value:$39.15M
Summary
Showing Top 3 of 123
About Capricor Therapeutics, Inc.
https://www.capricor.comCapricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $5.92M ▲ | $-24.57M ▲ | 0% | $-0.54 ▲ | $-24.08M ▲ |
| Q2-2025 | $0 | $5.67M ▼ | $-25.91M ▼ | 0% | $-0.57 ▼ | $-27.23M ▼ |
| Q1-2025 | $0 ▼ | $6.07M ▲ | $-24.39M ▼ | 0% ▲ | $-0.53 ▼ | $-24.58M ▼ |
| Q4-2024 | $11.13M ▲ | $4.27M ▲ | $-7.12M ▲ | -63.94% ▲ | $-0.16 ▲ | $-7.32M ▲ |
| Q3-2024 | $2.26M | $3.46M | $-12.56M | -555.2% | $-0.38 | $-12.65M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $98.57M ▼ | $126.44M ▼ | $42.57M ▲ | $83.87M ▼ |
| Q2-2025 | $122.8M ▼ | $133.57M ▼ | $28.59M ▲ | $104.98M ▼ |
| Q1-2025 | $144.78M ▼ | $153.77M ▼ | $26.12M ▲ | $127.65M ▼ |
| Q4-2024 | $151.52M ▲ | $170.48M ▲ | $25.02M ▲ | $145.46M ▲ |
| Q3-2024 | $85.03M | $92.95M | $24.69M | $68.26M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 ▲ | $0 ▲ | $0 ▼ | $0 ▼ | $0 ▲ | $0 ▲ |
| Q2-2025 | $-25.91M ▼ | $-20.12M ▼ | $14.55M ▼ | $19.58K ▼ | $-5.55M ▼ | $-21.57M ▼ |
| Q1-2025 | $-24.39M ▼ | $-6.43M ▲ | $23.89M ▲ | $50.35K ▼ | $17.51M ▲ | $-7.57M ▲ |
| Q4-2024 | $-7.12M ▲ | $-14.8M ▼ | $-123.38M ▼ | $81.09M ▲ | $-57.09M ▼ | $-15.53M ▼ |
| Q3-2024 | $-12.56M | $-11.64M | $2M | $67.33M | $57.69M | $-11.7M |
CEO
Linda Marbán
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2019-06-05 | Reverse | 1:10 |
| 2013-11-21 | Reverse | 1:50 |
ETFs Holding This Stock
Summary
Showing Top 3 of 55
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
B. Riley Securities
Buy
Maxim Group
Buy
HC Wainwright & Co.
Buy
Roth Capital
Buy
Jones Trading
Buy
Oppenheimer
Outperform
Grade Summary
Showing Top 6 of 8
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:2.87M
Value:$69M
VANGUARD GROUP INC
Shares:2.21M
Value:$53.05M
BLACKROCK INC.
Shares:1.63M
Value:$39.15M
Summary
Showing Top 3 of 123